Brain, Kidney & Peripheral

heartwire News

  • Alert FDA Clears Betrixaban (Bevyxxa) for VTE Prophylaxis Betrixaban is the first and only anticoagulant for hospital and extended-duration prophylaxis of VTE in hospitalized, acutely medically ill patients at risk for VTE.
  • Lying Flat vs Sitting Up: No Difference in Stroke Outcomes The HeadPoST study -- showing no difference in disability outcomes in stroke patients who were laid flat vs those sitting up for the first 24 hours -- has now been published in the New England Journal of Medicine.
  • Registry Data Support NOACs for Single-Risk-Factor AF Ischemic strokes rates were similar between atrial fibrillation patients treated with novel oral anticoagulants and warfarin, but imbalances in the study groups have raised questions.
  • Canakinumab Cuts Secondary CV Events in Phase 3 CANTOS Top-line results show the monoclonal antibody, given on top of standard care, significantly reduced the risk of cardiovascular death, nonfatal MI, and nonfatal stroke in patients with a prior MI and elevated CRP.


  • Rethinking the 'Cause' of Depression   Dr Stephen Strakowski proposes a novel way to think about depression etiology and discusses what it means for treatment.
  • NSAIDs and CV Risk: The Bottom Line A man with a previous heart attack requires pain management for osteoarthritis. Which agent is safest?
  • NOACs for AFib: The Right Dose Matters   Dr Arefa Cassoobhoy highlights one of the week's important news stories for primary care.
  • EHRA The Danger of AF Without Symptoms Atrial fibrillation symptoms are bothersome and cause anxiety, but they could be a blessing in disguise. A presentation at EHRA finds that patients without symptoms fare worse in terms of clinical events.